Co-LAB AccelBio
- Company typePrivate
- Founded2021
- HeadquartersCantanhede, Portugal
- Headcount11–50
- GTM typeB2B
- OfferingServices
Co-LAB AccelBio firmographics
Firmographics- Name
- Co-LAB AccelBio
- Legal name
- Laboratório Colaborativo AccelBio
- Website
- https://accelbio.pt
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Co-LAB AccelBio industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Lab Automation, Instrument Control & Workflow Orchestration Software (HLAGAJAG)
Keywords
Where Co-LAB AccelBio is headquartered
LocationHeadquarters
- HQ city
- Cantanhede
- HQ country
- Portugal
- HQ region
- Europe
Offices2 records
Markets served
Co-LAB AccelBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Research Grants and Funding: Funding from Portuguese and European sources including La Caixa Foundation, FCT, COMPETE2030, European Commission, EIT Health, and Mission Interface to support R&D activities and drug discovery projects
- Open Call Awards: Financial awards of up to 50,000 EUR offered to selected projects through competitive open calls to support drug discovery services and consumables
- Drug Discovery Services: Provides drug discovery and development services to academic institutions, biotech companies, and pharmaceutical partners through its technology platforms and expertise
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Open Call 2024 Award |
Go-to-market motion3 records
Distribution channels1 record
Marketing channels8 records
Co-LAB AccelBio product offering
Product offeringCore offering
Co-LAB AccelBio is a Portuguese collaborative laboratory that operates a vertically integrated drug discovery platform combining hiPSC-derived organoid technology, advanced in vitro systems, high-throughput screening, and computational medicinal chemistry. It selects fundamental biomedical research discoveries and cutting-edge technology platforms, guiding their transformation into validated and investment-worthy therapeutic assets covering target validation, hit identification, lead optimization, and early ADMET. Services are delivered to academic researchers, biotech startups, and pharmaceutical companies through direct collaboration, open calls, and grant-funded programs.
Product overview
Co-LAB AccelBio is a Collaborative Laboratory that operates as a unified drug discovery platform combining multiple technology modules and services. The core portfolio includes the OrganTech hiPSC-derived organoid platform, Advanced in vitro systems with microfluidic devices, a High-Throughput Screening Platform, and Computational Medicinal Chemistry Services—all working together within a vertically integrated R&D approach covering target validation, hit identification, lead optimization, and early ADMET. The Bio-Transfer program extends this ecosystem by bridging academic research to commercial applications. Together, these products form an end-to-end drug discovery engine designed to translate breakthrough biomedical science into validated, investment-worthy therapeutic assets.
Differentiator
Problem solved
Functional benefit
Products and services
- OrganTech (Organoids Platform) A cutting-edge platform using hiPSC-derived organoids (heart, liver, lung, kidney, CNS, gastrointestinal) to accelerate preclinical studies and reduce Phase 1 clinical trial risks. Provides vertically integrated drug discovery services for CNS, cardiovascular, and kidney therapeutic areas covering target validation, hit identification, lead optimization, and early ADMET.
- High-Throughput Screening Platform
Quantifiable outcome
- 22 proposals evaluated and 2 projects selected for support through Open Call 2024
- +3 more outcomes
Companies that use Co-LAB AccelBio
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Co-LAB AccelBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Co-LAB AccelBio partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core, major and minor.
- Biocant ParkcoreCo-organizer of BIO-Europe Spring 2026 conference in Lisbon; host venue for AccelBio operations and events; joint Host Committee member for Portugal National Booth
- P-BIO (Portuguese Bioindustry Association)coreCo-organizer of BIO-Europe Spring 2026 and joint Host Committee member; represents Portuguese biotech industry ecosystem
- AICEP Portugal GlobalmajorSupporting role in BIO-Europe Spring 2026 through dedicated stand and networking event; co-organizer of EIT Morning Health Talks
- Instituto de Medicina Molecular (iMM)coreKey associate and academic partner; host of International Advisory Board meeting; collaborator on intellectual property workshops and drug discovery projects
- Health from Portugal (HfPT) Mobilizing AgendamajorLed by Prologica, approved under Portuguese Economic Recovery and Resilience Plan; aims to position Portugal as world reference hub in health solutions; AccelBio investment of 708,779.76 EUR
- IMPACT EU ConsortiumcoreEIC Pathfinder initiative for novel cardiovascular disease therapies using AI-based integration of clinical and multi-omics data; AccelBio joined through Hop-On mechanism
- BIO-RED ConsortiummajorEuropean Commission-funded consortium supporting development and adoption of green technologies in red biotechnology; 7-country initiative strengthening regional biotech ecosystems
- EIT HealthmajorSupported EIT Morning Health Talks event; partnership for healthcare innovation ecosystem development and UK healthcare mission
- GiMM (Gulbenkian Institute for Molecular Medicine)coreAcademic partner for immune modulation research; collaborated on La Caixa Foundation-funded project targeting T cell activity for inflammation treatment
- FCT (Encontro Ciência 2024)minorCo-organizer of Encontro Ciência 2024 science exhibition alongside University of Porto and Ciencia Viva
- Tel Aviv University (Blavatnik Center for Drug Discovery)minorInternational collaboration visit to learn about academic innovation and technology transfer methodologies in Israeli ecosystem
- Weizmann Institute of ScienceminorInternational collaboration through Bina and Yeda technology transfer offices to explore innovation methodologies
- Medicen Paris RegionmajorHost of BIO-RED partner meeting in Paris; European biotech cluster advancing interregional roadmap and ecosystem-building initiatives
- AbbVieminorJoachim Vogt, Director Search & Evaluation International at AbbVie, participated as speaker at AccelBio workshop on industry-academic collaborations
- Consorzio ItalbiotecminorHost of IMPACT EU consortium 2nd Year Meeting in Milan
- CoLAB TrialscorePartner in Bio-Transfer project for biomedical commercialization alongside i3S and AccelBio
- i3ScoreLead partner in Bio-Transfer project alongside AccelBio and CoLAB Trials for biomedical knowledge commercialization
Scale indicators6 records
Recent moves3 records
Expansion highlights7 records
Co-LAB AccelBio competitors and assessment
Company assessmentDirect peers
- Evotec: Global preclinical drug discovery CRO offering target identification, hit identification, lead optimization, and ADMET services across multiple therapeutic areas. Directly comparable to AccelBio's vertically integrated drug discovery service model, but at much larger scale.
- InSphero: Swiss specialty CRO offering organoid-based in vitro models for drug safety and efficacy testing. Closely comparable to AccelBio's Organoids Platform (3D organoid disease models) and targets the same pharma and biotech customers for preclinical human-relevant testing.
- CN Bio Innovations: UK-based organ-on-chip company providing single- and multi-organ MPS platforms for drug discovery and safety assessment. Comparable technology overlap with AccelBio's microfluidic hiPSC organoid systems, and a similar go-to-market of selling into pharma preclinical pipelines.
- Mimetas: Dutch organ-on-chip company offering microfluidic 3D tissue models for drug discovery and toxicology. Direct competitor in the human-relevant preclinical model space and a natural peer to AccelBio's hiPSC-derived organoid and microfluidic device platforms.
- Sygnature Discovery: UK-based integrated drug discovery CRO providing medicinal chemistry, in vitro biology, DMPK, and in vivo pharmacology services. Comparable as a mid-sized preclinical CRO with a full target-to-candidate workflow, like AccelBio's vertically integrated approach.
- Crown Bioscience: Global preclinical CRO with oncology-focused translational platforms and in vivo / in vitro services. Comparable as a translational services CRO that bridges academic discoveries and pharma pipelines — the same role AccelBio plays for Portuguese biotech.
Broad incumbents
- Charles River Laboratories: Large global CRO with significant preclinical and discovery services, including safety assessment and laboratory sciences. Comparable as a broad preclinical services incumbent; AccelBio is a niche, regionally focused version of the discovery services Charles River offers.
- Eurofins Discovery: Large commercial discovery services arm of Eurofins offering assay development, screening, ADMET, and in vitro pharmacology. Comparable as a broad commercial drug discovery services provider that competes for pharma outsourcing budgets relevant to AccelBio's services.
Emerging players
- Hesperos: US-based organ-on-chip specialist developing multi-organ human-on-a-chip systems for preclinical drug testing. Comparable as an emerging organoid / MPS-focused player serving pharma preclinical needs with human-relevant models.
- Bicycle Therapeutics: Clinical-stage biotech with a distinctive platform (bicyclic peptides) and roots in academic collaboration. Comparable as a platform-driven, academic-collaboration-oriented biotech that grew out of a translational lab model — illustrative of the longer-term trajectory AccelBio is positioning for.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Co-LAB AccelBio social profiles
Digital presenceCo-LAB AccelBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Co-LAB AccelBio leadership team
Management profileNumber of profiles
Profiles2 records
Co-LAB AccelBio funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Co-LAB AccelBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Co-LAB AccelBio
What does Co-LAB AccelBio do?
Co-LAB AccelBio is a Portuguese collaborative laboratory that operates a vertically integrated drug discovery platform combining hiPSC-derived organoid technology, advanced in vitro systems, high-throughput screening, and computational medicinal chemistry. It selects fundamental biomedical research discoveries and cutting-edge technology platforms, guiding their transformation into validated and investment-worthy therapeutic assets covering target validation, hit identification, lead optimization, and early ADMET. Services are delivered to academic researchers, biotech startups, and pharmaceutical companies through direct collaboration, open calls, and grant-funded programs.
Is Co-LAB AccelBio a public or private company?
Co-LAB AccelBio is a private company. It is classified as unknown and is currently operating.
When was Co-LAB AccelBio founded?
Co-LAB AccelBio was founded in 2021. It employs 11 to 50 people.
Where is Co-LAB AccelBio based?
Co-LAB AccelBio is headquartered in Cantanhede, Portugal, in the Europe region.
How does Co-LAB AccelBio make money?
Three revenue lines are on record. Research Grants and Funding is the primary driver. The others are open Call Awards and drug Discovery Services.
Who are Co-LAB AccelBio's main competitors?
Direct peers on record are Evotec, InSphero, CN Bio Innovations, Mimetas, Sygnature Discovery and Crown Bioscience. Broad incumbents are Charles River Laboratories and Eurofins Discovery. Emerging players are Hesperos and Bicycle Therapeutics.
Does Co-LAB AccelBio have an API?
No public API is recorded for Co-LAB AccelBio.
What industry is Co-LAB AccelBio in?
Co-LAB AccelBio's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.